Neuca

Neuca EBIT Growth

The Year-over-Year EBIT Growth of Neuca (NEU.WA) as of Oct 21, 2026 is -14.98 %. In the previous year, Year-over-Year EBIT Growth was 3.64 % — a change of -511.68% (lower).

EBIT Growth

-14.98 %

YoY

-511.68%

Last updated:

Year-over-Year EBIT Growth of Neuca is 2025 -14.98 % . Year-over-Year EBIT Growth of Neuca was 2024 3.64 % . It decreases by -511.68% lower compared to the previous year.

The Neuca EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
4.32 PLN
Jan 1, 2019
23.75 PLN
Jan 1, 2020
35.30 PLN
Jan 1, 2021
-5.22 PLN
Jan 1, 2022
19.74 PLN
Jan 1, 2023
9.84 PLN
Jan 1, 2024
3.64 PLN
Jan 1, 2025
-14.98 PLN
The Neuca EBIT Growth history
YEAREBIT GrowthYoY
-14.98 %-511.68%
3.64 %-63.02%
9.84 %-50.14%
19.74 %-477.94%
-5.22 %-114.79%
35.30 %+48.62%
23.75 %+449.75%
4.32 %-134.62%
-12.48 %-175.57%
16.51 %-70.43%
55.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Year-over-Year EBIT Growth of Neuca is -14.98 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Neuca since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Neuca historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Neuca

All Key Metrics — Neuca